Worldwide initiative for diabetes education symposium in partnership with diabetes congress 2020
The prevalence of hypoglycaemia in patients with type 2 diabetes (T2DM), the impact on patient morbidity and mortality, and the increased risk of cardiovascular (CV) mortality that it causes are all under-recognized. There is a demonstrated need for physicians to understand the triggers, signs, and risk factors for hypoglycaemia in T2DM, its effect on patients, and the best ways to avoid it.
This symposium will begin with a global overview of T2DM and then address the risks of hypoglycaemia and how, if untreated, it can lead to significant CV events. Treatment possibilities and approaches that lower the risk of hypoglycaemia, as well as associated CV risk, will be discussed so that physicians can learn how to prevent, detect, and manage such events in their T2DM patients. Evidenced-based data on combination therapy, as well as insulin intensification will also be discussed, along with information on how to manage clinical inertia. Finally, a review of the impact of recent cardiovascular outcomes trials (CVOTs) will shed light on the importance of treatment choices.
At the conclusion of the program, participants will be able to: 1) recognize the association between glycaemic variability as a predictor of hypoglycaemia and the clinical implications of hypoglycaemia in T2DM patients; 2) understand approaches to preventing hypoglycaemia; 3) explain when and how it is appropriate to intensify insulin therapy in T2DM patients, as well as manage clinical inertia; 4) • Implement new treatment strategies to reduce cardiovascular risk as a result of hypoglycemia, and overall cardiovascular risk as evidenced by recent CVOTs with new diabetes therapies.